key: cord-1019573-b3wd182c
authors: Bassi, Andrea; Azzarelli, Andrea; Vaccaro, Angelina; Mazzatenta, Carlo
title: At home dose escalation of Propranolol for Infantile Hemangiomas during the COVID‐19 Pandemic
date: 2020-07-07
journal: Dermatol Ther
DOI: 10.1111/dth.13977
sha: 0e11e4f8cb1fa8a834d3f1b87d23f9dd24cb55aa
doc_id: 1019573
cord_uid: b3wd182c

nan

The novel coronavirus disease 2019 (COVID-19) has drastically changed our life and the healthcare delivery worldwide. A widespread reduction in ambulatory visits has been documented for all the different specialties in order to minimize the risk of exposure and transmission of COVID-19.

Therefore, the use of telemedicine has been widely implemented in different dermatological fields giving the opportunity to rapidly identify new clinical entities related to the pandemic virus (1, 2) and to be able to follow up patients with chronic skin diseases (3, 4) . Infantile hemangiomas (IH) often requires urgent evaluation and risk stratification to determine which infants need treatment and which one could be managed with continued observation (5) . Since most of the IH growth is between 1 and 3 months, prompt initiation of therapy with propranolol is the gold standard for those children requiring treatment. As the need for early treatment could be hindered by parents' fear to access public hospitals during the pandemic period, since the last days of February we encouraged pediatricians and colleagues to send us pictures (via email or WhatsApp) to perform a first screening of patients with higher risk IH needing beta-blocker treatment (5) . From March to May 2020 we identified 7 children with IH at high risk of scarring and/or disfigurement due to the localization (face, eye) or early ulceration and requiring propranolol treatment. We decided to perform at least one direct clinical evaluation since the received pictures were often of low quality, posing a risk of misleading (Figure 1 ). After confirming indication for propranolol therapy, all the patients, in the same day, carried out a cardiologic and a pediatric evaluation. If no This article is protected by copyright. All rights reserved.

contraindications were present, treatment was immediately started at the standard dose of 1 mg/kg daily in two divided doses. Usually, as a standard of care, children come back a week later to increase the dosage to 2 mg/kg daily and the third week to achieve the maximum daily dosage of 3 mg/kg. During these clinical controls blood pressure, heart rate, glycemic stick and weight of the child are usually evaluated.

In this emergency situation, to avoid unnecessary access to our Hospital heavily engaged in the treatment of COVID-19 patients, we decided, after informed consent, to slowly increase the dose of the drug at home and to monitor the treatment by telemedicine with parents and with the referring pediatrician. We considered ethically correct to implement this protocol, given to the high safety profile of propranolol, with an almost complete absence of adverse events when properly used (6).

In our "emergency" protocol, we addressed families to increase the dose of the drug by 25% each

week achieving the dosage of about 2 mg/kg daily (1.95 mg/kg) after 3 weeks and the maximum dosage of about 3 mg/kg daily (3.05 mg/kg) after 5 weeks (Figure 2) . We decided to scale up the dose of propranolol to the maximum dose suggested, as it has been clearly demonstrated that there are no differences of adverse events incidence between 1, 2 or 3mg/kg (7). Parents were thoroughly counseled about clinical signs of potential adverse events and advised to immediately discontinue the drug and promptly inform us and the community pediatrician in case of sign/symptom such as cough, wheezing, gastrointestinal symptoms or lethargy. In all cases no adverse effects were reported and, in line with literature data, a good response has been observed. To date our patients are still followed-up with the aid of telemedicine and a control visit has been planned at the 6th month of therapy. We found this protocol really helpful to manage our patients in this particular period however we believe that further studies are needed to confirm that at home scale-up of This article is protected by copyright. All rights reserved.

propranolol could be also used in non-pandemic period, in order to reduce disease burden for families in term of travel, loss of working-days and costs.

Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients

Chilblain-like lesions during the COVID-19 pandemic: should we really worry?

Teledermatology in the Wake of COVID-19: Advantages and Challenges to Continued Care in a Time of Disarray

Did Whatsapp® reveal a new cutaneous COVID-19 manifestation?

Management of Infantile Hemangiomas during the COVID Pandemic

Propranolol in the treatment of infantile